PERSISTENCE WITH BISPHOSPHONATE THERAPY AND RISK OF HIP FRACTURE

被引：0
|
作者：
Chodick, G. [1 ]
Shalev, V [1 ]
Sharon, Y. [2 ]
Goldstein, I [1 ]
机构：
[1] Maccabi Healthcare Serv, Tel Aviv, Israel
[2] Tel Aviv Univ, IL-69978 Tel Aviv, Israel
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.691
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A124 / A124
页数：1
相关论文
共 50 条
  • [31] Bisphosphonate use and subsequent hip fracture in South Korea
    Y.-K. Lee
    Y.-C. Ha
    H. J. Choi
    S. Jang
    C. Park
    Y.-T. Lim
    C. S. Shin
    Osteoporosis International, 2013, 24 : 2887 - 2892
  • [32] Does Preoperative Bisphosphonate Use Impact the Risk of Periprosthetic Fracture Following Total Hip Arthroplasty?
    Torres, Rodnell Busigo
    Hong, James
    Kodali, Hanish
    Poeran, Jashvant
    Stern, Brocha Z.
    Hayden, Brett L.
    Chen, Darwin D.
    Moucha, Calin S.
    JOURNAL OF ARTHROPLASTY, 2025, 40 (03):
  • [33] Adherence to bisphosphonate therapy is associated with decreased nonvertebral osteoporotic fracture risk.
    Silverman, S
    Siris, E
    Abbott, T
    Barr, C
    Harris, S
    Rosen, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S286 - S286
  • [34] Increased Imminent Fracture Risk in Liver Transplant Recipients Despite Bisphosphonate Therapy
    Begin, Marie-Josee
    Ste-Marie, Louis-Georges
    Huard, Genevieve
    Dorais, Marc
    Rakel, Agnes
    TRANSPLANTATION PROCEEDINGS, 2023, 55 (03) : 576 - 585
  • [35] Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference
    Beard, Mary K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (01) : 141 - 147
  • [36] Duration of Bisphosphonate Therapy and the Risk of Atypical Femur Fracture in Rheumatic Disease Patients
    Saldanha, Lisa
    Bell, Mary
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1243 - 1244
  • [37] Is persistence to bisphosphonate therapy related only to dosing regimen?
    Van Staa, T.
    Leufkens, H.
    Cooper, C.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : 375 - 375
  • [38] Is persistence to bisphosphonate therapy related only to dosing regimen?
    van Staa, T. P.
    Leufkens, H. G. M.
    Cooper, C.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S77 - S77
  • [39] Bisphosphonate therapy and hip fractures within the risedronate and alendronate (REAL) cohort study: Subgroup with prior fracture
    Delmas, P. D.
    Silverman, S. L.
    Watts, N. B.
    Lange, J. L.
    Lindsay, R.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S221 - S221
  • [40] Erratum to: Incidence of second hip fracture and compliant use of bisphosphonate
    Y.-K. Lee
    Y.-C. Ha
    B.-H. Yoon
    K.-H. Koo
    Osteoporosis International, 2014, 25 : 2327 - 2327
12345